IPSC Stock Price, 2 Quote, Chart

Market Summary

USD3.01-0.12

Delayed

-3.83%

IPSC Stock Price

View Fullscreen

IPSC RSI Chart

IPSC Valuation

Market Cap

249.4M

Price/Earnings (Trailing)

-1.87

Price/Sales (Trailing)

111.58

EV/EBITDA

-1.68

Price/Free Cashflow

-2.53

IPSC Price/Sales (Trailing)

IPSC Profitability

EBT Margin

-5941.70%

Return on Equity

-75.03%

Return on Assets

-38.3%

Free Cashflow Yield

-39.56%

IPSC Fundamentals

IPSC Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

-50.29%

Rev. Growth (Qtr)

-60.61%

IPSC Earnings

Earnings (TTM)

-133.5M

Earnings Growth (Yr)

10.24%

Earnings Growth (Qtr)

28.77%

Breaking Down IPSC Revenue

Last 7 days

-3.8%

Last 30 days

6.0%

Last 90 days

-36.0%

Trailing 12 Months

-5.6%

How does IPSC drawdown profile look like?

IPSC Financial Health

Current Ratio

12.44

Debt/Equity

0.02

Debt/Cashflow

-23.9

IPSC Investor Care

Shares Dilution (1Y)

39.05%

Diluted EPS (TTM)

-2.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	6.6M	5.3M	7.4M	2.2M
2022	0	0	0	5.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 2

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	russotti gregory	sold	-15,619	3.1238	-5,000	see remarks
May 03, 2024	farid adrienne	sold	-2,835	3.106	-913	chief operations officer
May 03, 2024	carr douglas	sold	-798	3.106	-257	svp finance & operations
Apr 22, 2024	russotti gregory	sold	-15,489	3.0979	-5,000	see remarks
Mar 07, 2024	pfeiffenberger brent	acquired	-	-	17,425	president and ceo
Mar 07, 2024	farid adrienne	acquired	-	-	24,000	chief operations officer
Mar 07, 2024	russotti gregory	acquired	-	-	24,000	see remarks
Mar 07, 2024	carr douglas	acquired	-	-	14,000	svp finance & operations
Mar 07, 2024	levitsky hyam	acquired	-	-	24,000	president of r&d
Mar 07, 2024	farid adrienne	acquired	23,515	1.03	22,831	chief operations officer

Which funds bought or sold IPSC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	reduced	-4.29	2,095	12,314	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-30.97	-7,683	51,038	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-2,955	9,844	-%
May 15, 2024	VR Adviser, LLC	new	-	14,233,500	14,233,500	0.68%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-45.66	-104,791	226,940	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-185,312	-	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	new	-	389,095	389,095	-%
May 15, 2024	Avidity Partners Management LP	reduced	-9.85	607,500	5,106,100	0.16%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	new	-	56,689	56,689	0.01%
May 15, 2024	Octagon Capital Advisors LP	new	-	2,257,200	2,257,200	0.27%

Are Funds Buying or Selling IPSC?

Are funds buying IPSC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IPSC

No. of Funds

Unveiling 2's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	bain capital life sciences opportunities iii, lp	6.6%	5,320,331	SC 13G
Apr 22, 2024	boxer capital, llc	5.8%	4,901,603	SC 13G
Apr 18, 2024	casdin capital, llc	6.08%	5,190,506	SC 13G
Apr 08, 2024	casdin capital, llc	4.95%	3,206,380	SC 13D/A
Mar 04, 2024	venrock healthcare capital partners iii, l.p.	5.4%	3,405,133	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	versant venture capital vi, l.p.	19.1%	11,452,014	SC 13G/A
Nov 13, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	versant venture capital vi, l.p.	19.4%	11,452,014	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of 2

View All Filings

Date Filed	Form Type	Document
May 15, 2024	S-3	S-3
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 06, 2024	144	Notice of Insider Sale Intent
May 03, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A

Peers (Alternatives to 2)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

2 News

Latest updates

2 Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-60.6%	855,000	2,170,500	3,486,000	99,000	1,720,000	2,081,500	1,411,000	1,396,000	1,058,000
Operating Expenses	-26.9%	32,164,000	44,030,000	35,774,000	35,176,000	33,801,000	33,827,000	33,962,000	32,747,000	38,494,000
S&GA Expenses	-100.0%	-	8,589,000	8,986,000	8,229,000	8,902,000	8,242,000	8,064,000	8,253,000	7,298,000
EBITDA Margin	1.6%	-53.32	-54.21	-15.33	-21.09	-16.95	-20.40	-	-	-
Interest Expenses	-100.0%	-	46,000	-	136,000	404,000	80,000	373,000	330,000	314,000
Income Taxes	100.1%	1,000	-869,000	592,000	950,000	1,208,000	32,000	25,000	18,000	16,000
Earnings Before Taxes	30.3%	-28,061,000	-40,267,000	-32,128,000	-32,341,000	-30,056,000	-31,650,000	-30,724,000	-30,970,000	-37,497,000
EBT Margin	1.5%	-59.42	-60.31	-17.08	-23.49	-18.67	-22.00	-	-	-
Net Income	28.8%	-28,062,000	-39,398,000	-32,720,000	-33,291,000	-31,264,000	-31,682,000	-30,749,000	-30,988,000	-37,513,000
Net Income Margin	2.3%	-59.72	-61.15	-17.46	-23.91	-18.87	-22.02	-	-	-
Free Cashflow	-13.1%	-30,787,000	-27,210,000	-16,914,000	-23,750,000	-34,210,000	-29,175,000	-34,050,000	-36,013,000	82,686,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-3.4%	349	361	398	417	456	487	512	533	550	437	470	496	107
Current Assets	12.9%	200	177	174	161	256	320	362	384	365	228	300	403	79.00
Cash Equivalents	3.1%	49.00	47.00	55.00	64.00	87.00	84.00	113	115	128	58.00	103	275	28.00
Net PPE	-3.8%	69.00	72.00	82.00	84.00	86.00	83.00	78.00	70.00	65.00	58.00	49.00	34.00	15.00
Liabilities	-3.0%	171	176	178	170	179	184	182	175	164	41.00	47.00	48.00	33.00
Current Liabilities	-10.0%	16.00	18.00	20.00	19.00	28.00	30.00	27.00	22.00	22.00	16.00	20.00	21.00	12.00
Long Term Debt	-	-	-	-	-	-	4.00	6.00	9.00	10.00	9.00	10.00	10.00	10.00
LT Debt, Non Current	-	-	-	-	-	-	4.00	6.00	9.00	10.00	9.00	-	-	10.00
Shareholder's Equity	-3.7%	178	185	219	248	277	303	330	358	387	396	423	448	-
Retained Earnings	-4.3%	-683	-655	-616	-583	-550	-519	-487	-456	-425	-388	-359	-333	-292
Additional Paid-In Capital	2.6%	862	840	837	832	829	824	821	818	815	785	783	782	218
Shares Outstanding	0%	60.00	60.00	60.00	59.00	59.00	55.00	58.00	57.00	57.00	58.00	25.00	12.00	-
Float	-	-	-	-	132	-	-	-	368	-	-	-	669	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-15.3%	-30,248	-26,230	-13,649	-19,250	-29,219	-22,907	-24,238	-25,556	86,753	-24,351	-23,983	-18,489	-22,179	-	-	-
Share Based Compensation	-10.0%	3,207	3,562	3,978	3,285	3,797	2,732	2,786	2,771	2,380	1,636	1,220	1,711	95.00	-	-	-
Cashflow From Investing	-38.0%	11,541	18,603	4,217	6,974	31,338	-4,273	22,664	12,518	-44,037	-20,602	-147,054	-11,648	-119,034	-	-	-
Cashflow From Financing	5211.0%	18,195	-356	300	-10,117	448	95.00	137	48.00	26,878	106	-466	224,649	193,485	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IPSC Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Collaboration revenue	$ 855	$ 1,720
Operating expenses
Research and development	23,421	24,899
General and administrative	8,743	8,902
Total operating expenses	32,164	33,801
Loss from operations	(31,309)	(32,081)
Interest expense		(404)
Interest income	3,237	2,623
Other income (expense)	11	(194)
Total other income (expense)	3,248	2,025
Loss before provision for income taxes	(28,061)	(30,056)
Provision for income taxes	(1)	(1,208)
Net Income (Loss)	$ (28,062)	$ (31,264)
Net loss per common share Basic (in dollars per share)	$ (0.45)	$ (0.53)
Weighted average common shares outstanding Basic (in shares)	62,296,637	58,610,375
Other comprehensive loss
Net Income (Loss)	$ (28,062)	$ (31,264)
Unrealized (loss) gain on investments	(351)	1,196
Foreign currency translation gain (loss)	(2)	9
Comprehensive loss	$ (28,411)	$ (30,077)

IPSC Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 46,812	$ 47,324
Short-term investments	145,204	125,414
Prepaid expenses and other current assets	7,797	4,256
Total current assets	199,813	176,994
Property and equipment, net	69,005	71,705
Operating lease right-of-use assets	19,314	20,376
Restricted cash	1,979	1,979
Long-term investments	57,852	89,096
Security deposits and non-current assets	544	541
Total assets	348,507	360,691
Current liabilities
Accounts payable	3,432	2,741
Accrued expenses and other liabilities	7,532	10,149
Deposit liability	491	584
Deferred revenue, current	4,610	4,372
Total current liabilities	16,065	17,846
Operating lease liability, long term	44,251	46,658
Security deposit, non-current	20
Deposit liability, non-current		56
Deferred revenue, non-current	110,288	111,381
Total liabilities	170,624	175,941
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value, 125,236,190 shares authorized; 60,335,701 and 58,473,660 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	6	6
Additional paid-in capital	861,951	840,407
Accumulated deficit	(683,833)	(655,771)
Accumulated other comprehensive loss	(241)	108
Total stockholders' equity	177,883	184,750
Total liabilities and stockholders' equity	$ 348,507	$ 360,691

About 2

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

CEO	Dr. Gregory Russotti Ph.D.
WEBSITE	centurytx.com
INDUSTRY	Biotechnology
EMPLOYEES	163

2 Frequently Asked Questions

What is the ticker symbol for 2? What does IPSC stand for in stocks?

IPSC is the stock ticker symbol of 2. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 2 (IPSC)?

As of Fri May 17 2024, market cap of 2 is 249.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IPSC stock?

You can check IPSC's fair value in chart for subscribers.

What is the fair value of IPSC stock?

You can check IPSC's fair value in chart for subscribers. The fair value of 2 is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 2 is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IPSC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 2 a good stock to buy?

The fair value guage provides a quick view whether IPSC is over valued or under valued. Whether 2 is cheap or expensive depends on the assumptions which impact 2's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IPSC.

What is 2's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, IPSC's PE ratio (Price to Earnings) is -1.87 and Price to Sales (PS) ratio is 111.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IPSC PE ratio will change depending on the future growth rate expectations of investors.